ProCE Banner Activity

TRIANGLE: Phase III Trial of Ibrutinib + CIT With or Without ASCT vs CIT Followed by ASCT in Younger Patients With Previously Untreated MCL

Slideset Download
Conference Coverage

Results from the phase III TRIANGLE study showed improved failure-free survival and acceptable safety with the addition of ibrutinib to standard CIT with or without ASCT in patients 65 years of age or younger with previously untreated MCL.

Released: December 16, 2022

Expiration: December 15, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen